nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—BCHE—kidney cancer	0.845	1	CbGaD
Mivacurium—Hypoxemia—Gemcitabine—kidney cancer	0.00902	0.0595	CcSEcCtD
Mivacurium—Doxacurium chloride—BCHE—kidney cancer	0.00326	1	CrCbGaD
Mivacurium—Hypoxia—Gemcitabine—kidney cancer	0.00285	0.0188	CcSEcCtD
Mivacurium—Wheezing—Everolimus—kidney cancer	0.00262	0.0173	CcSEcCtD
Mivacurium—Phlebitis—Vinblastine—kidney cancer	0.00228	0.0151	CcSEcCtD
Mivacurium—Phlebitis—Dactinomycin—kidney cancer	0.0018	0.0119	CcSEcCtD
Mivacurium—Injection site reaction—Gemcitabine—kidney cancer	0.0018	0.0119	CcSEcCtD
Mivacurium—Bradycardia—Pazopanib—kidney cancer	0.00175	0.0115	CcSEcCtD
Mivacurium—Cardiac disorder—Temsirolimus—kidney cancer	0.00169	0.0112	CcSEcCtD
Mivacurium—Bronchospasm—Everolimus—kidney cancer	0.00167	0.011	CcSEcCtD
Mivacurium—Angiopathy—Temsirolimus—kidney cancer	0.00165	0.0109	CcSEcCtD
Mivacurium—Immune system disorder—Temsirolimus—kidney cancer	0.00165	0.0109	CcSEcCtD
Mivacurium—Mediastinal disorder—Temsirolimus—kidney cancer	0.00164	0.0108	CcSEcCtD
Mivacurium—Flushing—Pazopanib—kidney cancer	0.00159	0.0105	CcSEcCtD
Mivacurium—Cardiac disorder—Pazopanib—kidney cancer	0.00159	0.0105	CcSEcCtD
Mivacurium—Erythema—Temsirolimus—kidney cancer	0.00159	0.0105	CcSEcCtD
Mivacurium—Angiopathy—Pazopanib—kidney cancer	0.00156	0.0103	CcSEcCtD
Mivacurium—Mediastinal disorder—Pazopanib—kidney cancer	0.00155	0.0102	CcSEcCtD
Mivacurium—Injection site reaction—Paclitaxel—kidney cancer	0.00151	0.00993	CcSEcCtD
Mivacurium—Erythema—Pazopanib—kidney cancer	0.0015	0.00986	CcSEcCtD
Mivacurium—Wheezing—Paclitaxel—kidney cancer	0.00147	0.0097	CcSEcCtD
Mivacurium—Muscle spasms—Pazopanib—kidney cancer	0.00144	0.00948	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Gemcitabine—kidney cancer	0.00136	0.00895	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.00134	0.00885	CcSEcCtD
Mivacurium—Anaphylactic shock—Temsirolimus—kidney cancer	0.0013	0.00854	CcSEcCtD
Mivacurium—Phlebitis—Paclitaxel—kidney cancer	0.00128	0.00842	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.00126	0.00834	CcSEcCtD
Mivacurium—Cardiac disorder—Everolimus—kidney cancer	0.00126	0.0083	CcSEcCtD
Mivacurium—Flushing—Everolimus—kidney cancer	0.00126	0.0083	CcSEcCtD
Mivacurium—Skin disorder—Temsirolimus—kidney cancer	0.00126	0.0083	CcSEcCtD
Mivacurium—Injection site reaction—Capecitabine—kidney cancer	0.00124	0.00815	CcSEcCtD
Mivacurium—Angiopathy—Everolimus—kidney cancer	0.00123	0.00811	CcSEcCtD
Mivacurium—Immune system disorder—Everolimus—kidney cancer	0.00122	0.00808	CcSEcCtD
Mivacurium—Mediastinal disorder—Everolimus—kidney cancer	0.00122	0.00806	CcSEcCtD
Mivacurium—Skin disorder—Pazopanib—kidney cancer	0.00119	0.00782	CcSEcCtD
Mivacurium—Erythema—Everolimus—kidney cancer	0.00118	0.00778	CcSEcCtD
Mivacurium—Mediastinal disorder—Erlotinib—kidney cancer	0.00118	0.00778	CcSEcCtD
Mivacurium—Arrhythmia—Erlotinib—kidney cancer	0.00117	0.00771	CcSEcCtD
Mivacurium—Bradycardia—Sunitinib—kidney cancer	0.00115	0.0076	CcSEcCtD
Mivacurium—Erythema—Erlotinib—kidney cancer	0.00114	0.00751	CcSEcCtD
Mivacurium—Muscle spasms—Everolimus—kidney cancer	0.00114	0.00748	CcSEcCtD
Mivacurium—Bronchospasm—Gemcitabine—kidney cancer	0.00112	0.00736	CcSEcCtD
Mivacurium—Flushing—Sorafenib—kidney cancer	0.00109	0.0072	CcSEcCtD
Mivacurium—Cardiac disorder—Sorafenib—kidney cancer	0.00109	0.0072	CcSEcCtD
Mivacurium—Angiopathy—Sorafenib—kidney cancer	0.00107	0.00704	CcSEcCtD
Mivacurium—Immune system disorder—Sorafenib—kidney cancer	0.00106	0.00701	CcSEcCtD
Mivacurium—Mediastinal disorder—Sorafenib—kidney cancer	0.00106	0.007	CcSEcCtD
Mivacurium—Arrhythmia—Sorafenib—kidney cancer	0.00105	0.00693	CcSEcCtD
Mivacurium—Cardiac disorder—Sunitinib—kidney cancer	0.00105	0.00693	CcSEcCtD
Mivacurium—Flushing—Sunitinib—kidney cancer	0.00105	0.00693	CcSEcCtD
Mivacurium—Phlebitis—Capecitabine—kidney cancer	0.00105	0.00691	CcSEcCtD
Mivacurium—Angiopathy—Sunitinib—kidney cancer	0.00103	0.00678	CcSEcCtD
Mivacurium—Erythema—Sorafenib—kidney cancer	0.00102	0.00676	CcSEcCtD
Mivacurium—Immune system disorder—Sunitinib—kidney cancer	0.00102	0.00675	CcSEcCtD
Mivacurium—Mediastinal disorder—Sunitinib—kidney cancer	0.00102	0.00673	CcSEcCtD
Mivacurium—Arrhythmia—Sunitinib—kidney cancer	0.00101	0.00667	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000998	0.00658	CcSEcCtD
Mivacurium—Flushing—Dactinomycin—kidney cancer	0.000995	0.00656	CcSEcCtD
Mivacurium—Erythema—Sunitinib—kidney cancer	0.000986	0.0065	CcSEcCtD
Mivacurium—Muscle spasms—Sorafenib—kidney cancer	0.000985	0.0065	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000963	0.00635	CcSEcCtD
Mivacurium—Muscle spasms—Sunitinib—kidney cancer	0.000948	0.00625	CcSEcCtD
Mivacurium—Tachycardia—Everolimus—kidney cancer	0.00094	0.0062	CcSEcCtD
Mivacurium—Skin disorder—Everolimus—kidney cancer	0.000936	0.00617	CcSEcCtD
Mivacurium—Erythema—Dactinomycin—kidney cancer	0.000933	0.00615	CcSEcCtD
Mivacurium—Skin disorder—Erlotinib—kidney cancer	0.000903	0.00595	CcSEcCtD
Mivacurium—Hypotension—Everolimus—kidney cancer	0.0009	0.00594	CcSEcCtD
Mivacurium—Cardiac disorder—Vincristine—kidney cancer	0.000889	0.00586	CcSEcCtD
Mivacurium—Angiopathy—Vincristine—kidney cancer	0.000869	0.00573	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000866	0.00571	CcSEcCtD
Mivacurium—Mediastinal disorder—Vincristine—kidney cancer	0.000863	0.00569	CcSEcCtD
Mivacurium—Dizziness—Temsirolimus—kidney cancer	0.000857	0.00565	CcSEcCtD
Mivacurium—Cardiac disorder—Gemcitabine—kidney cancer	0.000844	0.00556	CcSEcCtD
Mivacurium—Anaphylactic shock—Sorafenib—kidney cancer	0.000836	0.00551	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000834	0.0055	CcSEcCtD
Mivacurium—Angiopathy—Gemcitabine—kidney cancer	0.000825	0.00544	CcSEcCtD
Mivacurium—Immune system disorder—Gemcitabine—kidney cancer	0.000821	0.00541	CcSEcCtD
Mivacurium—Mediastinal disorder—Gemcitabine—kidney cancer	0.000819	0.0054	CcSEcCtD
Mivacurium—Rash—Temsirolimus—kidney cancer	0.000817	0.00538	CcSEcCtD
Mivacurium—Dermatitis—Temsirolimus—kidney cancer	0.000816	0.00538	CcSEcCtD
Mivacurium—Skin disorder—Sorafenib—kidney cancer	0.000812	0.00536	CcSEcCtD
Mivacurium—Arrhythmia—Gemcitabine—kidney cancer	0.000812	0.00535	CcSEcCtD
Mivacurium—Dizziness—Pazopanib—kidney cancer	0.000807	0.00532	CcSEcCtD
Mivacurium—Injection site reaction—Doxorubicin—kidney cancer	0.000797	0.00525	CcSEcCtD
Mivacurium—Erythema—Gemcitabine—kidney cancer	0.000791	0.00522	CcSEcCtD
Mivacurium—Skin disorder—Sunitinib—kidney cancer	0.000782	0.00515	CcSEcCtD
Mivacurium—Bradycardia—Paclitaxel—kidney cancer	0.000775	0.00511	CcSEcCtD
Mivacurium—Rash—Pazopanib—kidney cancer	0.000769	0.00507	CcSEcCtD
Mivacurium—Dermatitis—Pazopanib—kidney cancer	0.000769	0.00507	CcSEcCtD
Mivacurium—Bronchospasm—Capecitabine—kidney cancer	0.000767	0.00506	CcSEcCtD
Mivacurium—Flushing—Paclitaxel—kidney cancer	0.000706	0.00466	CcSEcCtD
Mivacurium—Cardiac disorder—Paclitaxel—kidney cancer	0.000706	0.00466	CcSEcCtD
Mivacurium—Angiopathy—Paclitaxel—kidney cancer	0.00069	0.00455	CcSEcCtD
Mivacurium—Immune system disorder—Paclitaxel—kidney cancer	0.000687	0.00453	CcSEcCtD
Mivacurium—Mediastinal disorder—Paclitaxel—kidney cancer	0.000686	0.00452	CcSEcCtD
Mivacurium—Anaphylactic shock—Vincristine—kidney cancer	0.000681	0.00449	CcSEcCtD
Mivacurium—Arrhythmia—Paclitaxel—kidney cancer	0.00068	0.00448	CcSEcCtD
Mivacurium—Phlebitis—Doxorubicin—kidney cancer	0.000675	0.00445	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000669	0.00441	CcSEcCtD
Mivacurium—Urticaria—Sorafenib—kidney cancer	0.000664	0.00438	CcSEcCtD
Mivacurium—Erythema—Paclitaxel—kidney cancer	0.000662	0.00437	CcSEcCtD
Mivacurium—Anaphylactic shock—Gemcitabine—kidney cancer	0.000646	0.00426	CcSEcCtD
Mivacurium—Dizziness—Vinblastine—kidney cancer	0.00064	0.00422	CcSEcCtD
Mivacurium—Dizziness—Everolimus—kidney cancer	0.000637	0.0042	CcSEcCtD
Mivacurium—Muscle spasms—Paclitaxel—kidney cancer	0.000637	0.0042	CcSEcCtD
Mivacurium—Hypotension—Vincristine—kidney cancer	0.000636	0.00419	CcSEcCtD
Mivacurium—Bradycardia—Capecitabine—kidney cancer	0.000636	0.00419	CcSEcCtD
Mivacurium—Skin disorder—Gemcitabine—kidney cancer	0.000627	0.00414	CcSEcCtD
Mivacurium—Dizziness—Erlotinib—kidney cancer	0.000615	0.00405	CcSEcCtD
Mivacurium—Rash—Everolimus—kidney cancer	0.000607	0.00401	CcSEcCtD
Mivacurium—Dermatitis—Everolimus—kidney cancer	0.000607	0.004	CcSEcCtD
Mivacurium—Hypotension—Gemcitabine—kidney cancer	0.000603	0.00398	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000601	0.00396	CcSEcCtD
Mivacurium—Rash—Erlotinib—kidney cancer	0.000586	0.00386	CcSEcCtD
Mivacurium—Dermatitis—Erlotinib—kidney cancer	0.000586	0.00386	CcSEcCtD
Mivacurium—Cardiac disorder—Capecitabine—kidney cancer	0.00058	0.00382	CcSEcCtD
Mivacurium—Flushing—Capecitabine—kidney cancer	0.00058	0.00382	CcSEcCtD
Mivacurium—Angiopathy—Capecitabine—kidney cancer	0.000567	0.00374	CcSEcCtD
Mivacurium—Immune system disorder—Capecitabine—kidney cancer	0.000564	0.00372	CcSEcCtD
Mivacurium—Mediastinal disorder—Capecitabine—kidney cancer	0.000563	0.00371	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00056	0.00369	CcSEcCtD
Mivacurium—Arrhythmia—Capecitabine—kidney cancer	0.000558	0.00368	CcSEcCtD
Mivacurium—Dizziness—Sorafenib—kidney cancer	0.000553	0.00365	CcSEcCtD
Mivacurium—Erythema—Capecitabine—kidney cancer	0.000544	0.00358	CcSEcCtD
Mivacurium—Anaphylactic shock—Paclitaxel—kidney cancer	0.000541	0.00356	CcSEcCtD
Mivacurium—Dizziness—Sunitinib—kidney cancer	0.000532	0.00351	CcSEcCtD
Mivacurium—Tachycardia—Paclitaxel—kidney cancer	0.000528	0.00348	CcSEcCtD
Mivacurium—Rash—Sorafenib—kidney cancer	0.000527	0.00348	CcSEcCtD
Mivacurium—Dermatitis—Sorafenib—kidney cancer	0.000527	0.00347	CcSEcCtD
Mivacurium—Skin disorder—Paclitaxel—kidney cancer	0.000525	0.00346	CcSEcCtD
Mivacurium—Muscle spasms—Capecitabine—kidney cancer	0.000523	0.00345	CcSEcCtD
Mivacurium—Rash—Sunitinib—kidney cancer	0.000507	0.00335	CcSEcCtD
Mivacurium—Dermatitis—Sunitinib—kidney cancer	0.000507	0.00334	CcSEcCtD
Mivacurium—Hypotension—Paclitaxel—kidney cancer	0.000505	0.00333	CcSEcCtD
Mivacurium—Rash—Dactinomycin—kidney cancer	0.00048	0.00317	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00046	0.00303	CcSEcCtD
Mivacurium—Dizziness—Vincristine—kidney cancer	0.00045	0.00297	CcSEcCtD
Mivacurium—Tachycardia—Capecitabine—kidney cancer	0.000433	0.00286	CcSEcCtD
Mivacurium—Skin disorder—Capecitabine—kidney cancer	0.000431	0.00284	CcSEcCtD
Mivacurium—Urticaria—Paclitaxel—kidney cancer	0.000429	0.00283	CcSEcCtD
Mivacurium—Rash—Vincristine—kidney cancer	0.000429	0.00283	CcSEcCtD
Mivacurium—Dermatitis—Vincristine—kidney cancer	0.000429	0.00283	CcSEcCtD
Mivacurium—Hypotension—Capecitabine—kidney cancer	0.000415	0.00273	CcSEcCtD
Mivacurium—Bradycardia—Doxorubicin—kidney cancer	0.00041	0.0027	CcSEcCtD
Mivacurium—Rash—Gemcitabine—kidney cancer	0.000407	0.00268	CcSEcCtD
Mivacurium—Dermatitis—Gemcitabine—kidney cancer	0.000407	0.00268	CcSEcCtD
Mivacurium—Flushing—Doxorubicin—kidney cancer	0.000374	0.00246	CcSEcCtD
Mivacurium—Cardiac disorder—Doxorubicin—kidney cancer	0.000374	0.00246	CcSEcCtD
Mivacurium—Angiopathy—Doxorubicin—kidney cancer	0.000365	0.00241	CcSEcCtD
Mivacurium—Immune system disorder—Doxorubicin—kidney cancer	0.000364	0.0024	CcSEcCtD
Mivacurium—Mediastinal disorder—Doxorubicin—kidney cancer	0.000363	0.00239	CcSEcCtD
Mivacurium—Arrhythmia—Doxorubicin—kidney cancer	0.00036	0.00237	CcSEcCtD
Mivacurium—Dizziness—Paclitaxel—kidney cancer	0.000358	0.00236	CcSEcCtD
Mivacurium—Urticaria—Capecitabine—kidney cancer	0.000352	0.00232	CcSEcCtD
Mivacurium—Erythema—Doxorubicin—kidney cancer	0.00035	0.00231	CcSEcCtD
Mivacurium—Rash—Paclitaxel—kidney cancer	0.000341	0.00225	CcSEcCtD
Mivacurium—Dermatitis—Paclitaxel—kidney cancer	0.000341	0.00225	CcSEcCtD
Mivacurium—Muscle spasms—Doxorubicin—kidney cancer	0.000337	0.00222	CcSEcCtD
Mivacurium—CHRM3—ureter—kidney cancer	0.000322	0.778	CbGeAlD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000296	0.00195	CcSEcCtD
Mivacurium—Dizziness—Capecitabine—kidney cancer	0.000293	0.00193	CcSEcCtD
Mivacurium—Anaphylactic shock—Doxorubicin—kidney cancer	0.000286	0.00189	CcSEcCtD
Mivacurium—Rash—Capecitabine—kidney cancer	0.00028	0.00184	CcSEcCtD
Mivacurium—Dermatitis—Capecitabine—kidney cancer	0.000279	0.00184	CcSEcCtD
Mivacurium—Tachycardia—Doxorubicin—kidney cancer	0.000279	0.00184	CcSEcCtD
Mivacurium—Skin disorder—Doxorubicin—kidney cancer	0.000278	0.00183	CcSEcCtD
Mivacurium—Hypotension—Doxorubicin—kidney cancer	0.000267	0.00176	CcSEcCtD
Mivacurium—Urticaria—Doxorubicin—kidney cancer	0.000227	0.0015	CcSEcCtD
Mivacurium—Dizziness—Doxorubicin—kidney cancer	0.000189	0.00125	CcSEcCtD
Mivacurium—Rash—Doxorubicin—kidney cancer	0.00018	0.00119	CcSEcCtD
Mivacurium—Dermatitis—Doxorubicin—kidney cancer	0.00018	0.00119	CcSEcCtD
Mivacurium—CHRM3—renal system—kidney cancer	2.56e-05	0.0618	CbGeAlD
Mivacurium—CHRM3—kidney—kidney cancer	2.47e-05	0.0598	CbGeAlD
Mivacurium—BCHE—nephron tubule—kidney cancer	2.3e-05	0.0555	CbGeAlD
Mivacurium—BCHE—cardiac atrium—kidney cancer	1.87e-05	0.0452	CbGeAlD
